Stumbled across some US commentary touting Mimedx (MDXG) and its up coming 2b knee OA trials with its drug Amniofix.
Wondering if anyone has done some comparison of this competition risk. Looks like PAR has the jump on them time wise, however yank analysts I've read are wildly bullish.
Disc. Long PAR. Apologies if previously discussed, couldn't see anything from searches.
research reports and media, page-1281
-
- There are more pages in this discussion • 3,124 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
0.010(4.55%) |
Mkt cap ! $80.45M | |||
| Open | High | Low | Value | Volume |
| 22.8¢ | 23.3¢ | 22.5¢ | $46.92K | 203.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 337 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 138166 | 5 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |